The AI powered platform centrally manages data from various sources. Credit: Chadchai Krisadapong / Shutterstock.

Eisai has adopted Medidata’s Clinical Data Studio, which aims to transform and modernising the clinical trial efficiency and patient experience.

Launched last month, this AI-driven platform is expected to grant Eisai control over its clinical data, facilitate the execution of scalable and complex trials, and enhance the overall patient experience.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Clinical Data Studio is a component of the Medidata platform, which centrally manages data from various sources. This integration could be crucial for improving data reliability across the entire trial ecosystem, the company noted.

Medidata global head of sales and executive vice-president Janet Butler said: “Through Clinical Data Studio, Eisai is enabling healthcare stakeholders to overcome the complexities of modern clinical trials and foster collaboration on cleaner, more actionable data.”

By combining data from Medidata sources such as Medidata Rave EDC and external sources, including laboratories or alternative electronic data capture systems, the Clinical Data Studio simplifies the data import process.

This approach also aids in automatic validation by configuring data transfer agreements.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The platform’s AI capabilities address the challenges of disparate data systems, offering up to an 80% quicker data review process. It also provides a comprehensive patient data view that can be reviewed, visualised, and acted upon simultaneously.

Eisai chief clinical science and operations officer Shobha Dhadda said: “We’ve included Medidata’s Clinical Data Studio in our clinical trial management platform given its ability to break down data silos and seamlessly integrate into our current software stack, while maintaining quality and integrity across all data sources.

“Having a suite of technology solutions capable of processing diverse clinical and patient data types provides increased efficiencies without sacrificing quality or needing additional resources.”

In May, Lexicon Pharmaceuticals selected Medidata to support its Phase IIb PROGRESS study of LX9211, a non-opioid candidate for the treatment of diabetic peripheral neuropathic pain.